Equities

Accuray Inc

Accuray Inc

Actions
  • Price (USD)1.63
  • Today's Change-0.04 / -2.40%
  • Shares traded511.51k
  • 1 Year change-55.22%
  • Beta1.4176
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.

  • Revenue in USD (TTM)430.55m
  • Net income in USD-21.49m
  • Incorporated2001
  • Employees1.02k
  • Location
    Accuray Inc1240 DEMING WAYMADISON 53717United StatesUSA
  • Phone+1 (608) 824-2800
  • Fax+1 (408) 716-4601
  • Websitehttps://www.accuray.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vivani Medical Inc0.00-25.65m109.68m44.00--4.90-----0.5042-0.50420.000.40680.00----0.00-52.93-56.58-60.80-67.66-------2,868.72----0.00-------84.69--40.33--
InfuSystem Holdings Inc127.41m84.00k137.14m499.002,316.552.6211.161.080.00280.00285.912.461.2310.666.57255,330.700.08114.600.09555.6950.2756.430.06594.071.511.560.36410.0014.4413.384,744.44--6.01--
Akoya Biosciences Inc93.57m-68.01m140.62m330.00--4.30--1.50-1.47-1.471.990.66320.60562.207.08283,554.50-44.01---56.06--55.99---72.68--2.38-10.150.7013--29.09--10.36------
Electromed Inc53.50m4.36m141.78m170.0033.143.3327.392.650.49420.49426.084.921.173.312.25314,682.309.497.8611.039.1476.4176.258.147.385.87--0.000.0015.3811.1737.3511.0024.58--
TELA Bio Inc63.15m-40.30m154.83m227.00--10.76--2.45-1.67-1.672.610.58340.96681.377.60278,180.60-61.70-52.00-79.77-60.9568.9765.32-63.82-107.653.23-8.520.7387--41.1347.85-5.35---17.12--
Accuray Inc430.55m-21.49m161.77m1.02k--3.94--0.3757-0.2197-0.21974.420.41390.91781.865.72420,462.90-4.58-1.45-7.84-2.4833.0637.86-4.99-1.620.778-0.38570.8086--4.122.03-73.56--13.92--
Semler Scientific Inc65.88m21.69m162.58m92.008.282.047.282.472.782.788.4511.260.85515.138.51716,097.8028.1438.8331.1444.4189.4390.2232.9232.5812.11--0.00--20.2825.9843.6932.64-0.3821--
Clearpoint Neuro Inc26.16m-20.63m170.01m107.00--4.92--6.50-0.8326-0.83261.051.260.50371.2610.08244,495.30-39.71-34.75-49.90-39.6757.1064.75-78.84-76.912.61--0.2237--16.5626.64-34.40--75.30--
Stereotaxis Inc27.10m-21.22m172.47m122.00--11.84--6.36-0.2575-0.25750.32880.24390.60121.456.14222,155.70-44.08-25.02-63.05-34.1255.1667.57-73.32-41.901.79--0.00---4.89-1.82-12.33--6.63--
CVRx Inc42.09m-52.01m179.03m200.00--2.70--4.25-2.48-2.482.013.070.36780.67815.64210,430.00-45.45---48.95--84.45---123.58--10.87-21.110.3064--74.89--0.5528------
Orchestra Biomed Holdings Inc2.22m-51.64m186.45m56.00--3.26--84.14-1.47-1.470.0631.600.02031.0130.9939,571.43-47.18---52.58--92.06---2,330.46--7.33--0.00---21.88---37.91------
Outset Medical Inc125.08m-168.77m186.64m480.00--2.00--1.49-3.38-3.382.501.800.35291.823.53260,577.10-47.61-41.40-54.98-47.2924.615.71-134.93-159.055.32-32.130.6786--13.00130.43-6.04--14.27--
Inogen Inc321.52m-96.68m208.19m834.00--1.08--0.6475-4.15-4.1513.818.150.9176.036.83385,519.20-27.57-8.23-34.28-9.5340.5444.54-30.07-10.312.36--0.00---16.32-2.49-22.30--26.34--
Delcath Systems Inc4.61m-49.79m210.33m76.00--13.17--45.65-2.65-2.650.23570.57470.13820.45454.5660,618.42-149.30-116.57-249.28-243.2170.5471.02-1,080.73-1,235.372.25-42.250.3348---24.05-9.53-30.60---5.26--
Butterfly Network Inc68.08m-121.92m217.03m225.00--1.06--3.19-0.5893-0.58930.3290.96850.20450.69544.97302,577.80-36.61---42.07--26.50---179.08--3.34--0.00---10.21--20.76------
Data as of May 17 2024. Currency figures normalised to Accuray Inc's reporting currency: US Dollar USD

Institutional shareholders

38.89%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20246.72m6.77%
Archon Capital Management LLCas of 31 Dec 20236.51m6.57%
Neuberger Berman Investment Advisers LLCas of 31 Dec 20235.50m5.54%
The Vanguard Group, Inc.as of 31 Mar 20245.06m5.10%
Royce & Associates LPas of 31 Dec 20233.23m3.26%
Heartland Advisors, Inc.as of 31 Mar 20242.92m2.94%
Renaissance Technologies LLCas of 31 Dec 20232.87m2.89%
Geode Capital Management LLCas of 31 Dec 20232.00m2.01%
D. E. Shaw & Co. LPas of 31 Dec 20231.92m1.93%
Harbert Fund Advisors, Inc.as of 31 Dec 20231.85m1.87%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.